Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies

Host: Steve Jackson, PharmD

Guest: Paolo F. Caimi, MD

Guest: Narendranath Epperla, MD, MS

As both CAR T-cell therapy and bispecific antibodies become increasingly integrated into the treatment of R/R LBCL, it’s important to consider the evidence in the context of individual patient factors and disease characteristics. In this conversation with Dr. Steve Jackson, Dr. Paolo Caimi and Dr. Naren Epperla examine the evidence guiding these approaches and discuss how they think about sequencing decisions in these patients. Dr. Caimi is the Associate BMT Director for Cellular Therapy at the Cleveland Clinic Cancer Institute and an Associate Professor in the Department of Medicine at the Case Western Reserve University School of Medicine. Dr. Epperla is an Associate Professor of Medicine and Associate Chief of Clinical Research in the Division of Hematology at the University of Utah Huntsman Cancer Institute.

This is a non-certified educational series produced and controlled by ReachMD.